Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modakafusp alfa + daratumumab in relapsed/refractory multiple myeloma
NCT05590377Phase 2Terminated
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Antibody Fragments, Immunomodulatory ADCs, Cytokines & Interferons
- Countries
- 7
01
Overview
A Phase 2 trial of modakafusp alfa in multiple myeloma (MM), sponsored by Teva Pharmaceutical Industries Ltd.. Started Jan 2023; status: terminated.
02
Drugs
modakafusp alfa
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05590377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05590377.